GB2598494B - A subunit vaccine for treatment or prevention of a respiratory tract infection - Google Patents

A subunit vaccine for treatment or prevention of a respiratory tract infection Download PDF

Info

Publication number
GB2598494B
GB2598494B GB2114836.6A GB202114836A GB2598494B GB 2598494 B GB2598494 B GB 2598494B GB 202114836 A GB202114836 A GB 202114836A GB 2598494 B GB2598494 B GB 2598494B
Authority
GB
United Kingdom
Prior art keywords
prevention
treatment
respiratory tract
tract infection
subunit vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2114836.6A
Other languages
English (en)
Other versions
GB202114836D0 (en
GB2598494A (en
Inventor
PERUGI Fabien
Schwamborn Klaus
Schuler Wolfgang
Lundberg Urban
Meinke Andreas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva SE
Original Assignee
Valneva SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva SE filed Critical Valneva SE
Publication of GB202114836D0 publication Critical patent/GB202114836D0/en
Publication of GB2598494A publication Critical patent/GB2598494A/en
Application granted granted Critical
Publication of GB2598494B publication Critical patent/GB2598494B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2114836.6A 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection Active GB2598494B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
EP17054134 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (3)

Publication Number Publication Date
GB202114836D0 GB202114836D0 (en) 2021-12-01
GB2598494A GB2598494A (en) 2022-03-02
GB2598494B true GB2598494B (en) 2024-07-24

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2114836.6A Active GB2598494B (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Country Status (21)

Country Link
US (3) US12162907B2 (enExample)
EP (1) EP3972639A1 (enExample)
JP (1) JP2022533318A (enExample)
KR (1) KR20220010478A (enExample)
CN (1) CN114127101A (enExample)
AU (1) AU2020277661A1 (enExample)
BR (1) BR112021021637A2 (enExample)
CA (1) CA3138064A1 (enExample)
CL (1) CL2021002819A1 (enExample)
CO (1) CO2021014694A2 (enExample)
EC (1) ECSP21079178A (enExample)
GB (1) GB2598494B (enExample)
IL (1) IL287099A (enExample)
MX (1) MX2021013111A (enExample)
MY (1) MY208001A (enExample)
PE (1) PE20220400A1 (enExample)
PH (1) PH12021552736A1 (enExample)
SA (1) SA521430813B1 (enExample)
SG (1) SG11202110646PA (enExample)
WO (1) WO2020234300A1 (enExample)
ZA (1) ZA202106883B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
IL297166A (en) 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
KR20230107621A (ko) 2020-11-13 2023-07-17 아이코사백스, 인크. 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
KR20230167017A (ko) * 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体：制造方法和用途
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119176858B (zh) * 2024-11-22 2026-01-09 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法
CN122011136A (zh) * 2026-04-13 2026-05-12 北京民海生物科技有限公司 一种融合前人偏肺病毒f蛋白的突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096993A2 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP4400115A3 (en) 2011-12-06 2024-10-23 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096993A2 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20180008697A1 (en) * 2014-12-24 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Recombinant metapneumovirus f proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL B. BATTLES ET AL: "Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein", NATURE COMMUNICATIONS, vol. 8, no. 1, 16 November 2017 (2017-11-16) *

Also Published As

Publication number Publication date
SA521430813B1 (ar) 2024-04-27
KR20220010478A (ko) 2022-01-25
CO2021014694A2 (es) 2022-01-17
US20240067681A1 (en) 2024-02-29
GB202114836D0 (en) 2021-12-01
GB2598494A (en) 2022-03-02
BR112021021637A2 (pt) 2021-12-21
EP3972639A1 (en) 2022-03-30
US20220185847A1 (en) 2022-06-16
WO2020234300A1 (en) 2020-11-26
PE20220400A1 (es) 2022-03-22
IL287099A (en) 2021-12-01
MY208001A (en) 2025-04-03
AU2020277661A1 (en) 2021-10-21
CA3138064A1 (en) 2020-11-26
MX2021013111A (es) 2021-11-17
CL2021002819A1 (es) 2022-07-08
ZA202106883B (en) 2022-07-27
JP2022533318A (ja) 2022-07-22
ECSP21079178A (es) 2021-11-30
US12162909B2 (en) 2024-12-10
US12162907B2 (en) 2024-12-10
CN114127101A (zh) 2022-03-01
PH12021552736A1 (en) 2022-07-11
SG11202110646PA (en) 2021-10-28
US20250171501A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
IL287099A (en) Subunit vaccine for the treatment and prevention of inflammatory diseases of the respiratory system
EP3925551C0 (en) CATHETER MOUTH DESIGNS
IL262104A (en) A mouthpiece for cooling a patient's oral tissue during therapeutic treatment
HUE058250T2 (hu) Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére
IL268127A (en) Preparations containing adrevan for oral or gastric administration and their use for treatment
HUE044731T2 (hu) Formulációk a száj, torok és respiratorikus traktus rendellenességeinek kezelésére
IL321414A (en) Vaccines against respiratory diseases
IL272562B1 (en) Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection
ES3030145T8 (en) Sars-cov-2 subunit vaccine
HK40072167A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
PT3609493T (pt) Tratamento de uma infeção vaginal bacteriana
GB202005231D0 (en) Method of mimimising patient risk
GB201912059D0 (en) Combaination therapy of a patient subgroup
GB202312455D0 (en) A vaccine for the treatment or prevention of Burkholderia species infection in a subject.
PL4153302T3 (pl) Leczenie wirusowych zakażeń dróg oddechowych
GB202015584D0 (en) Treatment for viral infection
ES3030310T8 (en) Sars-cov-2 subunit vaccine
IL275152A (en) System for hypothermia treatment of a patient
IL284669A (en) Gel type pharmaceutical composition for treating/preventing an infection
IL275150A (en) System for hypothermia treatment of a patient
IL310974A (en) Prevention of lower respiratory tract infection with NIRSEVIMAB
GB202110146D0 (en) Treatment of respiratory conditions
ZA201907779B (en) Fabric for preventing/treating upper respiratory tract infection
GB202004452D0 (en) Respiratory treatment device
AU2018900409A0 (en) Treatment of respiratory infection (3)